Apellis Pharmaceuticals Announces Preliminary 2023 Financial Results

Details

announced preliminary unaudited U.S. net product revenues for the fourth quarter and full year 2023. The company reported approximately $114 million in revenue from SYFOVRE and $24 million from EMPAVELI for the fourth quarter, with total revenues of approximately $366 million for the full year. These figures are subject to finalization following the completion of the company's financial closing procedures. The detailed press release, including further financial details, is furnished as Exhibit 99.1.

Items reported

Exhibits (1)

About Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing novel therapeutic compounds to address complement-mediated diseases. The primary focus of Apellis is to pioneer medicines leveraging targeted inhibition of the complement system, a key component of the immune system that plays a crucial role in a variety of diseases. The company's flagship product, targeting diseases such as geographic atrophy and paroxysmal nocturnal hemoglobinuria (PNH), highlights its commitment to addressing unmet medical needs with innovative treatments. Apellis Pharmaceuticals operates in the highly competitive pharmaceutical and biotechnology industry, collaborating with healthcare providers and research institutions to advance clinical treatment options. Headquartered in Waltham, Massachusetts, its contributions to medical science are significant, paving the way for advancements in immunology and therapy development. As a publicly traded entity, Apellis influences the healthcare sector by enhancing treatment paradigms and offering new hope for patients with chronic and debilitating conditions.